144. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. https://www.fda.gov/ Drugs/DrugSafety/ucm635038.htm. Published 2019. Accessed April 19 2019. 145. American Psychiatric Association. DSM-5, Diagnostic and Statistical Manual of Mental Disorders: Fifth ed. Washington DC: American Psychiatric Association; 2013. 146. Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug and alcohol dependence. 2016;169:117-127. 147. National Academies of Sciences Engineering and Medicine. Medications for opioid use disorder save lives. The National Academies Press. 2019:doi: https://doi. org/10.17226/25310. 148. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186- 216. 149. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug and alcohol dependence. 2009;105(1- 2):9-15. 150. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32-51. 151. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. 152. Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants. www.fda. gov/Drugs/DrugSafety/ucm575307.htm. Published 2017. Accessed May 15 2019. 153. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455-470. 154. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. British journal of anaesthesia. 2006;96(5):627-632. 155. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75. 156. American Society of Addiction Medicine. Buprenorphine Waiver Management. https://www.asam.org/ resources/practice-resources/buprenorphine-waiver- management#NPPA. Published 2019. Accessed May 15 2019. 157. Fareed A, Patil D, Scheinberg K, et al. Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow- up. Journal of addictive diseases. 2013;32(3):244-251. 158. Rosenthal RN, Lofwall MR, Kim S, et al. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. Jama. 2016;316(3):282-290. 159. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. The Cochrane database of systematic reviews. 2011(4):CD001333. 160. Binswanger IA, Glanz JM. Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. Drug Saf. 2018;41(10):979-980. 161. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668.
162. Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. J Subst Abuse Treat. 2015;57:75-80. 163. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513. 164. Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction. 2012;107(5):943-952. 165. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. The American journal of medicine. 2013;126(1):74 e11-77. 166. Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013;108(10):1788-1798. 167. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238-1246. 168. Schwartz RP. When Added to Opioid Agonist Treatment, Psychosocial Interventions do not Further Reduce the Use of Illicit Opioids: A Comment on Dugosh et al. Journal of addiction medicine. 2016;10(4):283-285. 169. Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction. 2012;107(9):1621- 1629. 170. Substance Abuse and Mental Health Services Administration. Buprenorphine. https://www.samhsa.gov/ medication-assisted-treatment/treatment/buprenorphine. Published 2019. Accessed May 15 2019. 171. Wakeman SE, Barnett ML. Primary Care and the Opioid- Overdose Crisis - Buprenorphine Myths and Realities. N Engl J Med. 2018;379(1):1-4. 172. Kennedy-Hendricks A, McGinty EE, Barry CL. Effects of Competing Narratives on Public Perceptions of Opioid Pain Reliever Addiction during Pregnancy. J Health Polit Policy Law. 2016;41(5):873-916. 173. Kennedy-Hendricks A, Busch SH, McGinty EE, et al. Primary care physicians’ perspectives on the prescription opioid epidemic. Drug and alcohol dependence. 2016;165:61- 70. 174. Woo J, Bhalerao A, Bawor M, et al. “Don’t Judge a Book Its Cover”: A Qualitative Study of Methadone Patients’ Experiences of Stigma. Subst Abuse. 2017;11:1178221816685087 175. Words matter handout. https://d14rmgtrwzf5a.cloudfront. net/sites/default/files/words_matter_handout.pdf. Accessed May 16 2019. 176. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. The Cochrane database of systematic reviews. 2013(12):CD006318. 177. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol. 1984;6(4):271-275. 178. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331. 179. Metz VE, Brown QL, Martins SS, Palamar JJ. Characteristics of drug use among pregnant women in the United States: Opioid and non-opioid illegal drug use. Drug and alcohol dependence. 2018;183:261-266.
180. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of internal medicine. 2006;144(2):127-134. 181. Jacobsen J, Jackson V, Dahlin C, et al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer. J Palliat Med. 2011;14(4):459-464. 182. Forrow L, Smith HS. Pain management in end of life: palliative care. In: Warfield CA BZ, ed. Principles & Practice of Pain Medicine. 2nd ed. New York, NY: McGraw-Hill; 2004. 183. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage. 2001;21(4):282-289. 184. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. The Lancet Oncology. 2003;4(5):312-318. 185. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011;61(3):157-182. 186. Keefe FJ, Abernethy AP, L CC. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol. 2005;56:601-630.
68
Powered by FlippingBook